Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Merck & Co., Inc.    MRK

MERCK & CO., INC.

(MRK)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
09/14/2020 09/15/2020 09/16/2020 09/17/2020 09/18/2020 Date
84.16(c) 84.21(c) 85.57(c) 85.64(c) 85.81(c) Last
8 183 210 10 330 789 9 905 007 7 719 928 11 575 380 Volume
-0.38% +0.06% +1.62% +0.08% +0.20% Change
More quotes
Financials (USD)
Sales 2020 47 947 M - -
Net income 2020 12 057 M - -
Net Debt 2020 15 643 M - -
P/E ratio 2020 18,1x
Yield 2020 2,82%
Sales 2021 51 388 M - -
Net income 2021 14 087 M - -
Net Debt 2021 13 088 M - -
P/E ratio 2021 15,6x
Yield 2021 3,04%
Capitalization 217 B 217 B -
EV / Sales 2020 4,85x
EV / Sales 2021 4,48x
Nbr of Employees 71 000
Free-Float 70,6%
More Financials
Company
Merck & Co., Inc. specializes in the development, production, and marketing of therapeutic products and vaccines sold under prescription. Net sales break down by activity as follows: - sale of pharmaceutical products (72.1%): for treating hypertension, osteoporosis, atherosclerosis, respiratory, bacterial and fungal, ophthalmologic, and urological diseases, acute migraine, hair loss in men, etc.; - sale of... 
Sector
Pharmaceuticals
Calendar
09/19Presentation
More about the company
Notations Surperformance© of Merck & Co., Inc.
Trading Rating : Investor Rating :
More Ratings
All news about MERCK & CO., INC.
12:32pMERCK : LYNPARZA Reduced Risk of Death by 31% vs. Enzalutamide or Abiraterone fo..
BU
10:21aMERCK : Presents Promising New Data for Three Investigational Medicines From Div..
BU
08:26aMERCK : and Eisai Present First-Time Data From Two Studies Evaluating KEYTRUDA® ..
BU
09/19MERCK : KEYTRUDA® (pembrolizumab) Reduced the Risk of Distant Metastasis or Deat..
BU
09/18AstraZeneca, Merck Say Lynparza Demonstrates Long-Term Progression-Free Survi..
DJ
09/18MERCK : LYNPARZA® (olaparib) Improved Median Progression-Free Survival to Over F..
BU
09/17MERCK : Vaccinex Shares Climb 18% on Keytruda Collaboration With Merck
DJ
09/17MERCK : to Hold Investor Briefing Following ESMO Virtual Congress 2020
AQ
09/16MERCK : to Present at the 2020 Cantor Fitzgerald Virtual Global Healthcare Confe..
AQ
09/16MERCK : to Hold Investor Briefing Following ESMO Virtual Congress 2020
BU
09/15SEATTLE GENETICS : and Merck Announce Two Strategic Oncology Collaborations
AQ
09/15MERCK : BRENZYS® (etanercept injection) now indicated for the Treatment of Plaqu..
AQ
09/15MERCK : to Present at the 2020 Cantor Fitzgerald Virtual Global Healthcare Confe..
BU
09/15MERCK : Makes $1 Billion Deal
DJ
09/15MERCK : HHS Can't Force Disclosure Of Drug Prices In Ads With "Blunderbuss" Rule
AQ
More news
News in other languages on MERCK & CO., INC.
09/14US-Konzern Merck & Co steigt für Krebsmittelforschung bei Seattle Genetics ei..
08/24MERCK : double approbation pour Keytruda au Japon
08/19MERCK : essai de phase III concluant sur Keytruda
08/19Erfolg für US-Pharmakonzern Merck & Co in Studie mit Krebsmedikament Keytruda
08/04MERCK : accord de licence dans la maladie NASH
More news
Analyst Recommendations on MERCK & CO., INC.
More recommendations
Chart MERCK & CO., INC.
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MERCK & CO., INC.
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 19
Average target price 96,06 $
Last Close Price 85,81 $
Spread / Highest target 24,7%
Spread / Average Target 11,9%
Spread / Lowest Target -2,11%
EPS Revisions
Managers
NameTitle
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis CFO & Executive Vice President-Global Services
Sandy Tremps Vice President-R&D IT CIO
Thomas Henry Glocer Independent Director
Leslie A. Brun Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
MERCK & CO., INC.-5.65%217 034
JOHNSON & JOHNSON2.27%392 765
ROCHE HOLDING AG9.27%322 209
PFIZER, INC.-6.02%203 549
NOVARTIS AG-9.76%200 978
NOVO NORDISK A/S12.50%161 415